AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Red Violet, you need to believe its identity data platform can keep finding new, high value use cases across regulated industries, with AI and analytics deepening customer reliance. The latest quarter’s higher sales and net income, combined with a sizeable capital raise, strengthen the financial base behind that thesis, but also sharpen the short term focus on how effectively the new capital is deployed and whether integration or execution missteps become the key risk.
The most relevant recent announcement is the roughly US$109 million public offering, which management plans to use for working capital and potential acquisitions. This sits squarely against the core catalyst of expanding into enterprise and government markets and broadening Red Violet’s data and technology stack, while also highlighting a fresh risk around acquisition pricing, cultural fit, and the possibility that new assets do not contribute meaningfully to margins or growth.
Yet behind the strong quarter and fresh capital, investors should also be aware of the concentration risk around key data suppliers and...
Read the full narrative on Red Violet (it's free!)
Red Violet's narrative projects $147.1 million revenue and $26.4 million earnings by 2029.
Uncover how Red Violet's forecasts yield a $79.00 fair value, a 12% upside to its current price.
Some of the lowest analysts were assuming around US$144.8 million of revenue and US$20.4 million of earnings by 2029, but they also worry rapid AI adoption by customers could erode Red Violet’s pricing power and cap growth, so your view on this risk might shift once you weigh those older expectations against the new earnings and cash raise.
Explore 2 other fair value estimates on Red Violet - why the stock might be worth 49% less than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com